Executive Snapshot
Core Diagnosis
Nigeria’s first Antimicrobial Resistance (AMR) action plan completed only 44% of its priority activities before expiring; its successor, NAP 2.0, corrected important weaknesses in costing and target-setting, but it does not yet make point-of-sale compliance sufficiently verifiable. Patent and Proprietary Medicine Vendors (PPMVs) are already barred from selling antibiotics, which fall outside the medicines their licence permits; in this channel, the human-side failure is compliance, plus a distinct treatment-adherence gap. Veterinary-side, we have not identified an enforceable statutory prescription-only classification attaching to the relevant antimicrobial classes. Both gaps converge at the counter, for different reasons, and neither is fixed by NAP 2.0’s redesign alone
Governance Implications
NAP 2.0 corrected important weaknesses in costing and target-setting, but it remains unclear whether its implementation architecture will produce verifiable compliance where antimicrobials are prescribed, sold and used. Unresolved is which named institution, Pharmacists Council of Nigeria (PCN), Federal Ministry of Livestock Development (FMLD), Veterinary Council of Nigeria (VCN) or National Agency for Food and Drug Administration and Control (NAFDAC), converts architecture into an enforceable requirement at the counter. One instrument will not suit both pathways.
Key Data Points
44% — NAP 1.0’s completion rate (2017–2022), according to federal assessment, the failure NAP 2.0 was built to correct.1
5–7% — projected GDP loss from AMR in developing countries by 2050, as cited in Nigeria’s One Health AMR situational analysis; not a Nigeria-specific estimate.2
40% — of surveyed antibiotic users in [Enugu State] reported completing their prescribed treatment; 49 per cent stopped once symptoms eased, while 8 per cent stopped because of cost. Evidence from Enugu State; not a national prevalence estimate.3
89.8% vs 4.4% — surveyed veterinarians overwhelmingly value susceptibility testing, but few request it routinely; reported barriers include cost and turnaround time.4
70% and 52% — of Oyo State Salmonella isolates were fluoroquinolone-resistant, while 52 per cent of sampled farms harboured ESBL-producing E. coli. Evidence from Oyo State poultry production; not a national prevalence estimate.5
Central Argument
Point-of-sale enforcement is necessary but not sufficient. It competes with dose completion on the human side and diagnostic cost on the veterinary side. Nigeria needs no new coordinating body; it needs each institution to convert its mandate into an enforceable, verifiable requirement, sequenced by what is possible now, what needs infrastructure, and what needs market change. On the human side, the goal is not simply to stop PPMVs selling antibiotics: it is to enforce that prohibition while ensuring enforcement does not push patients into a different informal market, which is why a referral-linked access pilot in underserved LGAs sits alongside compliance enforcement.
Policy Watchpoints
● Whether PCN activates and publishes LGA PPMV compliance data, rather than relying on the existing restriction alone
● Whether FMLD, VCN and NAFDAC complete the legal determination for classifying the National Essential Veterinary Medicines List and Guidelines (NEVML)’s antimicrobial classes as prescription-only, and implement the resulting classification, ahead of NAP 2.0’s next implementation phase
● Whether NAFDAC and VCN complete the supply-chain mapping and launch a poultry-scoped sales-surveillance pilot that makes veterinary enforcement verifiable rather than asserted
● Whether PCN and state health authorities launch the underserved-LGA referral-access pilot, so that stricter PPMV enforcement does not simply displace patients into another informal market.
Strategic Context
Defining the Enforcement Gap
Nigeria’s first National Action Plan on AMR, NAP 1.0 (2017–2022), completed only 44% of its priority activities1, a shortfall attributed to weak cross-sectoral involvement and a plan that was never costed. NAP 2.0 (2024–2028) corrected important weaknesses in costing and target-setting, but it does not yet make point-of-sale compliance sufficiently verifiable.
This Perspective stays inside one boundary: what happens between national AMR policy and the point antimicrobials are sold and used, and which institution can close that gap. It is not a survey of the global AMR crisis or Nigeria’s healthcare system generally. The stakes are concrete: Nigeria’s AMR burden has been recognised as a significant economic and public-health challenge, with projections indicating that AMR-related GDP losses in developing countries could reach 5–7% by 2050, a developing-country projection rather than a Nigeria-specific estimate. This paper tests point-of-sale enforcement against the constraints that compete with it: affordability, diagnostic capacity, prescribing behaviour, surveillance, compliance incentives, and reports which bind where evidence allows.
Why This Question Is Open Now
Three developments create a live decision window. FMLD validated Nigeria’s first National Essential Veterinary Medicines List and Guidelines6 (NEVML) in November 2025, an explicit prescribing framework issued as guidance; we have not identified an enforceable statutory prescription-only classification attaching to its antimicrobial classes. A 2025 governance review7 confirms antibiotic sales remain largely unregulated. The next phase of NAP 2.08 can still be redirected before it is designed, not after.
Institutional Failure
Who Holds the Authority
“No recommendation here is addressed to an institution until its mandate is checked.”
|
Institution |
Controls |
Does not control |
|
NAFDAC |
Registration, quality and import/manufacture approval of drugs, human and veterinary; enforcement against unregistered products |
Day-to-day prescribing or dispensing conduct at point of sale |
|
PCN |
Licensing of pharmacy and PPMV premises; the OTC list a PPMV may legally sell, which already excludes antibiotics
|
Manufacture/import registration; veterinary medicines |
|
VCN |
Registration and licensing of veterinary surgeons and premises; professional discipline |
Veterinary para-professionals and agro-vet retail staff, a statutory gap the Council has flagged; it could not be confirmed whether any amendment is currently before the National Assembly |
|
FMLD |
Veterinary policy leadership; holds the NEVML and CVO Nigeria office |
Enforcement power, which sits with VCN and NAFDAC, not the Ministry |
|
NCDC / AMR Coordinating Committee |
Cross-sectoral coordination across Nigeria’s AMR surveillance network (14 human-sector and 6 animal-sector sentinel sites)8 |
Enforcement power over any point-of-sale actor; role is convening |
Two findings follow. For PPMVs, the human-side legal gap assumed to exist does not exist: antibiotics are already outside a PPMV’s lawful authority9; the problem is compliance. On the veterinary side, we have not identified an enforceable statutory prescription-only classification attaching to the relevant antimicrobial classes. Existing VCN and NAFDAC mandates provide possible institutional routes for enforcement, but the exact statutory instrument required to establish prescription-only classification for veterinary antimicrobials should be determined through legal review.
The Human Pathway: Three Problems, Not One
Prescription enforcement asks if the antibiotic was authorised. Correct dispensing asks if the right drug, dose and duration were supplied. Treatment adherence asks whether the patient followed the prescribed treatment instructions, including the recommended drug, dose and duration. Enforcement addresses the first, may influence the second, but does not by itself resolve adherence to prescribed treatment.
PPMVs are already barred from selling antibiotics.10 The failure is enforcement, not the rule: reviews across Sub-Saharan Africa11 find antibiotics sold without prescription routinely, in incomplete doses. In Enugu State3 — evidence from one Nigerian setting and not a national prevalence estimate — only 40% of surveyed antibiotic users reported completing the prescribed course; 49% stopped as soon as they felt better, while 8% stopped once the doses they could afford ran out. This suggests that an affordability-only intervention would address only one part of the adherence challenge.
The Veterinary Pathway: A Longer Chain, More Caution
A 2025 survey4 found 89.8% of vets value susceptibility testing, yet only 4.4% request it every time — cost and turnaround, not indifference, being the reason. NAFDAC’s 2019 feed-additive ban did not create a general prescription requirement, and a 2025 review7 confirms veterinary sales remain largely unregulated. The NEVML is guidance: we have not identified an enforceable statutory prescription-only classification attaching to the relevant veterinary antimicrobial classes, which makes this a legal-architecture gap, not merely a compliance gap.
These studies are single-state assessments that provide evidence of AMR risks within specific Nigerian settings; they should not be interpreted as national prevalence estimates. A 2025 Oyo assessment5 found that 70% of Salmonella isolates were fluoroquinolone-resistant and that 52% of sampled farms harboured ESBL-producing E. coli. These findings provide evidence of resistance concerns in a Nigerian production setting but should not be interpreted as a national prevalence estimate. A Jos study12 provided evidence of resistance risks within the sampled poultry production environment rather than a national estimate of prevalence. Enugu slaughterhouse13 sampling identified multidrug-resistant Campylobacter among sampled isolates, indicating a local food-chain risk that requires further investigation rather than establishing national transmission patterns.
Where the Pathways Converge, and Where They Do Not
Both pathways share a locus, the point of sale, not a mechanism. On the human-side, the failure is compliance plus a separate dose-completion problem. On the veterinary-side, no enforceable statutory prescription-only classification has been identified, and willing prescribers still face cost constraints a new rule will not remove. Enforcement concerns compliance; stewardship concerns judgement absent enforcement. One recommendation fits neither sector precisely.
Political Economy
Why the Incentive Gap Persists
Weak enforcement reflects incentives regulation has not altered.
● Patients may weigh the immediate cost of continuing prescribed treatment against a less visible future resistance risk, with some discontinuing treatment once symptoms improve.
● PPMVs depend on medicine sales; a compliant seller loses the sale to one who is not. They also fill a genuine access gap where pharmacists are scarce, enforcement without an alternative could cut access along with misuse.
● Farmers see prescription and testing as added cost against a flock-loss risk prophylactic use manages cheaply.
● Vets are scarce in production areas; agro-vet retailers face the same undercutting dynamic as PPMVs, and antimicrobial use substitutes cheaply for biosecurity investment, externalising the resistance cost onto the health system.
The operative question is what behaviour stricter enforcement would actually change, and what it would cost the actors involved. The Reform Agenda below answers that per pathway.
Reform Agenda
Four Reform Pillars, Seven Actions
The seven actions below sit under four reform pillars. Each action still names one owner, one concrete first action, and one measure of success; sequencing within each pillar reflects what is administratively actionable now, what needs infrastructure, and what needs market change, not importance.
Pillar 1: Make Human Dispensing Rules Enforceable and Visible
PPMV compliance, lawful dispensing counselling, and access safeguards.
a. Make PPMV Compliance Data Public
Action: PCN strengthens its existing sub-national compliance structures, including relevant LGA-level PPMV regulatory mechanisms where established, and publishes quarterly LGA-level compliance rates and aggregate inspection and sanction data from spot-checks on antibiotic sales, starting with outlets already on its licence register. Individual outlets are identified only once a violation has been formally established under the applicable enforcement process. This adapts the functional lesson of Denmark’s Yellow Card model14, that measured behaviour linked to thresholds and enforcement can make a rule consequential, without treating a livestock prescribing-control system as institutionally equivalent to PPMV inspections.
Owner and timeline: PCN; within 6 months of adoption.
Success metric: Share of inspected PPMV outlets found non-compliant, published quarterly by LGA.
b. Separate Treatment-Adherence Support from Prescription Enforcement
Action: PCN should require a standard treatment-adherence counselling protocol within PCN-regulated pharmacy and dispensing premises and verify its use through routine inspection, supporting adherence to prescribed treatment instructions and addressing early discontinuation after symptom improvement. The same counselling principles should be adapted by relevant health authorities for facility-based dispensing environments.
Owner and timeline: PCN for the counselling protocol and its inspection in regulated premises, concurrent with pathway (a); state health authorities, working with NCDC and the primary health care system or through an independent periodic survey, for measuring patient adherence.
Success metric: Dispensing compliance (PCN): share of inspected PCN-regulated premises with the adherence-counselling protocol in place and applied, published alongside the pathway (a) compliance data. Patient adherence (health system): reported completion of prescribed treatment among sampled patients, measured by state health authorities, NCDC or a periodic independent survey rather than by PCN. PCN owns dispensing compliance; the health system measures patient adherence.
c. Pilot Referral-Linked Access in Underserved LGAs
Action: PCN and state health authorities designate a small set of underserved LGAs where PPMVs are the only accessible outlet, and pilot a referral-linked access model: PPMVs triage and refer suspected bacterial infections to the nearest prescribing facility, with phone-in or telemedicine prescription review where distance is prohibitive, rather than permitting PPMV antibiotic dispensing itself, which no current legal route authorises. This preserves access without reopening the prohibition pathway a is built to enforce.
The pilot should therefore assess not only referral completion but also access to lawful dispensing points, including referral distance, prescription turnaround time, treatment-seeking delays and whether patients return to informal antibiotic purchasing when lawful access remains difficult.
Owner and timeline: PCN and state health authorities; pilot design within 6 months.
Success metric: Change in treatment-seeking delay in pilot LGAs versus matched non-pilot LGAs.
Pillar 2: Build an Enforceable Veterinary Antimicrobial Regime
Legal classification and sales monitoring.
d. Commission a Legal Determination for Veterinary Prescription-Only Classification
Action: Within 90 days, FMLD commissions, with VCN and NAFDAC, a legal determination of the existing statutory route for classifying the NEVML’s antimicrobial classes as prescription-only, including the institutional pathway required to establish enforceable veterinary antimicrobial controls.15 Following the legal determination, the competent authority identified through that process should implement the required classification through the appropriate legal instrument, whether a gazette notice, regulation or another authorised mechanism.
Owner and timeline: FMLD, with VCN and NAFDAC; legal determination within 3 months, classification implemented on the timeline that determination sets.
Success metric: Completion and publication of the legal determination within 90 days; publication of the resulting legal instrument, classification decision and effective date thereafter.
e. Launch a Veterinary Antimicrobial Sales-Surveillance Pilot
Action: NAFDAC and VCN should first map the poultry antimicrobial supply chain — including manufacturers, importers, distributors, registered veterinary premises and retailers — to determine which actors fall within existing regulatory authority, which actors can operationally provide sales data, and what reporting obligations can lawfully be established. NAFDAC should then design a phased reporting mechanism based on the actors and legal authorities identified through the mapping exercise, beginning with those categories for which reporting obligations can be clearly established. This adapts Denmark’s VetStat logic to what Nigeria’s current registers and NAFDAC’s reporting authority can actually support.
Owner and timeline: NAFDAC, with VCN; supply-chain mapping and authority review within 6 months; pilot design and launch in 3 states within 12 months of that review.
Success metric: Completion of the supply-chain mapping and authority review within 6 months; thereafter, share of the actors identified as reportable that are submitting monthly sales data.
Pillar 3: Connect Antimicrobial Use to One Health Surveillance
Interoperable human-animal reporting and alerts.
f. Build Interoperable One Health AMR Surveillance
Action: The AMR Coordinating Committee establishes interoperable surveillance between its 14 human-sector and 6 animal-sector sentinel sites: harmonised surveillance definitions, antimicrobial susceptibility testing standards and priority resistance indicators, shared data standards, joint alert thresholds, defined referral pathways, and routine cross-sectoral reporting of priority resistant organisms, so matching or unusual resistance signals identified across human and animal surveillance can trigger cross-sectoral investigation. The EU’s ESVAC programme16 illustrates what linked sales-and-surveillance data can support: ESVAC-reporting countries recorded a 53 per cent reduction in veterinary antibiotic sales between 2011 and 2022, alongside a wider package of regulatory restrictions, monitoring, alternatives and producer support rather than surveillance alone.
Owner and timeline: NCDC-led AMR Coordinating Committee; protocol issued within 12 months.
Success metric: Resistant-pathogen signals cross-referenced monthly between the two systems.
Pillar 4: Make Compliance Economically Possible
Access alternatives, extension services, vaccination and biosecurity.
g. Bundle Veterinary Restriction with Extension Support
Action: FMLD should add antimicrobial stewardship and biosecurity training to existing livestock extension programmes and explore mechanisms for improving access to preventive alternatives, including vaccination, so that restrictions introduced under pathway d are accompanied by practical options for producers. This responds to the incentive problem identified earlier in this Perspective: where disease prevention systems are weak or costly, antimicrobial use may remain an economically rational short-term risk-management strategy for producers. International experience suggests that antimicrobial restrictions are more sustainable when combined with monitoring, producer engagement and feasible alternatives to routine antimicrobial use.17
Owner and timeline: FMLD extension services, with state veterinary authorities and relevant livestock-health partners; stewardship and biosecurity curriculum update within 12 months, with preventive-support mechanisms identified alongside implementation planning.
Success metric: Initial success measure: establishment of stewardship and biosecurity support mechanisms linked to producer outreach. Longer-term success measure: change in reported prophylactic versus therapeutic antimicrobial use once sales-surveillance data and farm-level monitoring systems are established.
Limitations
This is a desk-based Perspective; no interviews or fieldwork were conducted.
● Core veterinary studies are single-state (Enugu, Oyo, Jos): they provide evidence of AMR risks in specific Nigerian settings but are not nationally representative prevalence estimates.
● This paper cannot attribute a specific share of Nigeria’s resistant-infection burden to either pathway; it reports association and plausible transmission, not causal attribution.
● Veterinary authority overlaps between FMLD, VCN and NAFDAC; the legal instrument for pathway d needs confirmation by counsel, not a literature review.
● Denmark’s and the EU’s reforms rest on data infrastructure and retail consolidation Nigeria does not yet have; each pathway names the specific condition limiting direct transfer.
Conclusion
From Enforcement Gap to Institutional Accountability
The central problem examined in this Perspective is not the absence of an AMR architecture, but the gap between that architecture and enforceable behaviour where antimicrobials are prescribed, sold and used. Nigeria has developed important institutional foundations: NAP 2.0 provides a more costed and targeted framework, the AMR Coordinating Committee provides a coordination mechanism, and the NEVML provides the veterinary sector with a foundation for stronger antimicrobial governance. These developments address important weaknesses identified under NAP 1.0, particularly around costing and target-setting. The remaining question is whether implementation arrangements now produce measurable compliance where antimicrobials are prescribed, sold and used.
The unresolved challenges differ across pathways. On the human side, the central issue is not the absence of a restriction on antibiotic sales by PPMVs but the gap between existing rules and compliance, alongside a separate treatment-adherence challenge. On the veterinary side, Nigeria must first complete the legal pathway for prescription-only classification, establish mechanisms for monitoring antimicrobial sales and address the economic incentives that make routine antimicrobial use attractive to producers.
International experience suggests that antimicrobial restrictions are more sustainable when sequenced alongside monitoring systems, producer engagement and feasible alternatives. Nigeria does not need to replicate any single model; it needs to establish an enforcement pathway suited to its own regulatory institutions and market conditions.
The task, therefore, is not simply to create more policy architecture, but to make existing institutions capable of translating rules into measurable behaviour. Nigeria needs to identify, for each pathway, who acts, what action is required, and how the system will verify that implementation has occurred. Closing the enforcement gap at the counter ultimately depends on moving from commitments on paper to accountability in practice.
Endnotes and Sources
1. World Health Organization Regional Office for Africa, “Nigeria Launches Action Plan to Combat Antimicrobial Resistance (AMR),” 20 October 2024, https://www.afro.who.int/countries/nigeria/news/nigeria-launches-action-plan-combat-antimicrobial-resistance-amr. Accessed 14 September 2026.
2. Nigeria Centre for Disease Control and Prevention. One Health Situational Analysis in Nigeria 2024. Abuja: NCDC, 2024. https://ncdc.gov.ng/themes/common/docs/protocols/351_1729270120.pdf. Accessed 24 August 2026).
3. Maduko, Winifred, Emmanuel Olamijuwon, Mike Kesby, and Jo Mhairi Hale. “Understanding Community Antibiotic Use and Antimicrobial Resistance in Sub-Saharan Africa: A Grassroots Perspective from Enugu, Nigeria.” PLOS ONE 21, no. 7 (2026): e0353762. https://doi.org/10.1371/journal.pone.0353762. Accessed 24 August 2026.
4. Daodu, Oluwafemi Babatunde, Esther Gbeja Olusegun, Godwin Adegbehingbe, Sola Emmanuel Komolafe, and Oluwakemi Christiana Daodu. “Barriers to Effective Antimicrobial Resistance Management in Nigerian Livestock: The Role of Veterinary Practices and Client Expectations.” BMC Veterinary Research 21 (2025): article 255. https://doi.org/10.1186/s12917-025-04710-2. Accessed 24 August 2026.
5. Adetunji, Victoria Olusola, Alistair Davies, Tom Chisnall, Mwapu Dika Ndahi, Idowu Oluwabunmi Fagbamila, Eme Ekeng, Ini Adebiyi, Olutayo Israel Falodun, and Roderick M. Card. “Genomic Diversity and Antibiotic Resistance of Escherichia coli and Salmonella from Poultry Farms in Oyo State, Nigeria.” Microorganisms 13, no. 6 (2025): article 1174. https://doi.org/10.3390/microorganisms13061174. Accessed 24 August 2026.
6. Federal Ministry of Livestock Development. “Nigeria Advances Animal Health with Vet Medicines List Validation.” 6 November 2025. https://fmld.gov.ng/news-details/76. Accessed 24 August 2026.
7. Adepoju, Victor Abiola, Abdulrakib Abdulrahim, and Bashar Haruna Gulumbe. “From Declarations to Accountability: Nigeria 2026 and the Global Fight against Antimicrobial Resistance.” Antimicrobial Resistance & Infection Control 14 (2025): article 138. https://doi.org/10.1186/s13756-025-01657-9. Accessed 24 August 2026.
8. Federal Ministries of Agriculture and Food Security; Environment; and Health and Social Welfare. One Health Antimicrobial Resistance: National Action Plan 2.0, 2024–2028. Federal Republic of Nigeria, April 2024. https://ncdc.gov.ng/themes/common/files/establishment/1f38432a65b71d397a2384dee3d87bd3.pdf. Accessed 24 August 2026.
9. Pharmacists Council of Nigeria. Reviewed PPMVL Guidelines for the Issuance of Patent and Proprietary Medicines Vendor’s Licence. S.I. No. 136 of 2019. Federal Republic of Nigeria Official Gazette 106, no. 131 (26 August 2019): B3033–B3038. https://pcn.gov.ng/wp-content/uploads/2024/11/PCN-Review-PPMVL-Guidelines-for-the-Issuance-of-Patent-and-Proprietary-Medicines-Vendors-Licence.pdf. Accessed 24 August 2026.
10. Beyeler, Naomi, Jenny Liu, and Maia Sieverding. “A Systematic Review of the Role of Proprietary and Patent Medicine Vendors in Healthcare Provision in Nigeria.” PLOS ONE 10, no. 1 (2015): e0117165. https://doi.org/10.1371/journal.pone.0117165. Accessed 15 September 2026.
11. Agu, Chibuike Innocent, Ifunanya Clara Agu, Chimdimma Obiobasi, Mahua Das, Rebecca King, Chinyere Mbachu, and Obinna Onwujekwe. “Scoping Literature Review of Antimicrobial Dispensing Practices among Patent Medicine Vendors in Sub-Saharan Africa.” Discover Public Health 22 (2025): article 719. https://doi.org/10.1186/s12982-025-01143-y. Accessed 24 August 2026.
12. Agusi, Ebere Roseann, et al. “Prevalence of Multidrug-Resistant Escherichia coli Isolates and Virulence Gene Expression in Poultry Farms in Jos, Nigeria.” Frontiers in Microbiology 15, no. 1 (2024): article 1298582. https://doi.org/10.3389/fmicb.2024.1298582. Accessed 24 August 2026.
13. Njoga, Emmanuel O., et al. “Campylobacter Colonisation of Poultry Slaughtered at Nigerian Slaughterhouses: Prevalence, Antimicrobial Resistance, and Risk of Zoonotic Transmission.” Tropical Medicine and Infectious Disease 10, no. 9 (2025): article 265. https://doi.org/10.3390/tropicalmed10090265 Accessed 24 August 2026.
14. Jensen, Vibeke Frøkjær, Leonardo Víctor de Knegt, Vibe Dalhoff Andersen, and Annette Wingstrand. “Temporal Relationship between Decrease in Antimicrobial Prescription for Danish Pigs and the ‘Yellow Card’ Legal Intervention Directed at Reduction of Antimicrobial Use.” Preventive Veterinary Medicine 17, no. 4 (2014): 554–564. https://doi.org/10.1016/j.prevetmed.2014.08.006. Accessed 24 August 2026.
15. Stege, Helle, Flemming Bager, Erik Jacobsen, and Annemette Thougaard. “VETSTAT—the Danish System for Surveillance of the Veterinary Use of Drugs for Production Animals.” Preventive Veterinary Medicine 57, no. 3 (2003): 105–115. https://doi.org/10.1016/S0167-5877(02)00233-7. Accessed 24 August 2026.
16. European Medicines Agency. Sales of Veterinary Antimicrobial Agents in 31 European Countries in 2022: Trends from 2010 to 2022. Thirteenth ESVAC Report. Luxembourg: Publications Office of the European Union, 2023. https://op.europa.eu/en/publication-detail/-/publication/59eda847-b429-11ee-b164-01aa75ed71a1/language-en. Accessed 24 August 2026.
17. American Association of Swine Veterinarians. “European Union Bans All Antibiotic Growth Promoters.” January 2006. https://www.aasv.org/2006/01/european-union-bans-all-antibiotic-growth-promoters/. Accessed 24 August 2026.